# Lisata Therapeutics, Inc.: overview LSTA · Nasdaq · CIK 320017 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lsta.md) · [Financials](/companies/lsta/financials.md) · [Filings](/companies/lsta/filings.md) · [Insiders](/companies/lsta/insiders.md) Latest reported revenue: [$0](/filings/0000320017-26-000038.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000320017-26-000038). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0000320017-25-000070.md) | [1,000 d](/filings/0000320017-26-000023.md) | [0.0](/filings/0000320017-26-000032.md) | [70.0](/filings/0000320017-26-000038.md) | [0.0](/filings/0000320017-25-000070.md) | [100 d](/filings/0000320017-26-000023.md) | [0.0](/filings/0000320017-26-000032.md) | [0.0](/filings/0000320017-26-000038.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(494.9%) d](/filings/0000320017-26-000023.md) | not reported | [(6954.3%)](/filings/0000320017-26-000038.md) | not reported | [(3079.0%) d](/filings/0000320017-26-000023.md) | not reported | not reported | | Net margin | % | not reported | [(461.0%) d](/filings/0000320017-26-000023.md) | not reported | [(6655.7%)](/filings/0000320017-26-000038.md) | not reported | [(2954.0%) d](/filings/0000320017-26-000023.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.59)](/filings/0000320017-25-000070.md) | not reported | [(0.55)](/filings/0000320017-26-000032.md) | [(0.54)](/filings/0000320017-26-000038.md) | [(0.49)](/filings/0000320017-25-000070.md) | not reported | [(0.50)](/filings/0000320017-26-000032.md) | [(0.32)](/filings/0000320017-26-000038.md) | | Free cash flow | $k | [(2,518) d](/filings/0000320017-25-000070.md) | [(4,528) d](/filings/0000320017-26-000023.md) | [(5,430)](/filings/0000320017-26-000032.md) | [(3,956) d](/filings/0000320017-26-000038.md) | [(3,342) d](/filings/0000320017-25-000070.md) | [(3,249) d](/filings/0000320017-26-000023.md) | [(3,083)](/filings/0000320017-26-000032.md) | [(2,649) d](/filings/0000320017-26-000038.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0000320017-24-000007.md) | [0.0](/filings/0000320017-25-000011.md) | [1.0](/filings/0000320017-26-000023.md) | [0.2](/filings/0000320017-26-000023.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(2240.9%)](/filings/0000320017-26-000023.md) | [(10711.2%)](/filings/0000320017-26-000023.md) | | Net margin | % | not reported | not reported | not reported | [(1998.5%)](/filings/0000320017-26-000023.md) | [(9756.5%)](/filings/0000320017-26-000023.md) | | Diluted EPS | $ per share | [(7.45)](/filings/0000320017-23-000011.md) | [(10.47)](/filings/0000320017-24-000007.md) | [(2.58)](/filings/0000320017-25-000011.md) | [(2.40)](/filings/0000320017-26-000023.md) | [(1.91)](/filings/0000320017-26-000023.md) | | Free cash flow | $m | [(22.3)](/filings/0000320017-23-000011.md) | [(21.5)](/filings/0000320017-24-000007.md) | [(20.0)](/filings/0000320017-25-000011.md) | [(19.4)](/filings/0000320017-26-000023.md) | [(16.0)](/filings/0000320017-26-000023.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lsta/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $948.0k | 278,837 | | Added +7,022 | | [Yakira Capital Management, Inc.](/funds/1584639.md) | 2026-06-30 | $471.1k | 138,561 | | New +138,561 | | [CSS LLC/IL](/funds/1103646.md) | 2026-06-30 | $375.4k | 110,422 | | Added +48,524 | | [DELTEC ASSET MANAGEMENT LLC](/funds/1269950.md) | 2026-06-30 | $282.9k | 83,197 | | Reduced −6,803 | | [Rangeley Capital, LLC](/funds/1517796.md) | 2026-06-30 | $275.4k | 81,000 | | Added +6,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $247.0k | 72,632 | | Added +1,745 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $186.5k | 54,857 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $166.5k | 48,964 | | Added +14,047 | | [GTS SECURITIES LLC](/funds/1452765.md) | 2026-06-30 | $102.7k | 30,200 | | Reduced −1,196 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $86.2k | 25,348 | | Unchanged | ## Recent filings [All 1,246 filings](/companies/lsta/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 10:38 ET | [DEF 14A](/filings/0001140361-26-039986.md) | Proxy statement, period 2026-11-09 | 0001140361-26-039986 | | 2026-10-14 | 20:25 ET | [8-K](/filings/0001140361-26-039602.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-039602 | | 2026-09-17 | 13:27 ET | [8-K](/filings/0001140361-26-036866.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-036866 | | 2026-08-06 | 20:03 ET | [10-Q](/filings/0000320017-26-000038.md) | Quarterly report, period 2026-06-30 | 0000320017-26-000038 | | 2026-08-04 | 10:01 ET | [8-K](/filings/0001140361-26-031028.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-031028 | | 2026-07-24 | 16:15 ET | [8-K](/filings/0001140361-26-029541.md) | 1.02 Termination of a material agreement; 8.01 Other events | 0001140361-26-029541 | | 2026-07-17 | 11:01 ET | [8-K](/filings/0001140361-26-028763.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-028763 | | 2026-06-09 | 11:30 ET | [8-K](/filings/0001140361-26-024560.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-024560 | | 2026-06-01 | 10:03 ET | [8-K](/filings/0001140361-26-023397.md) | 8.01 Other events | 0001140361-26-023397 | | 2026-05-29 | 20:50 ET | [8-K](/filings/0001140361-26-023336.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-023336 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000320017-26-000023.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1a307e81-1871-406a-9fe2-782e667c84f1) ## About the filer - CIK: 320017 - Tickers: LSTA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.